Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    23348814 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers
Condition: Infections, Meningococcal
Intervention: Biological: Meningococcal vaccine GSK134612
2 Completed Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
Condition: Invasive Neisseria Meningitidis Serogroup Diseases
Intervention: Biological: Meningococcal vaccine GSK134612

Indicates status has not been verified in more than two years